Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure |
| |
Authors: | Shao-Wen Jiang Peng Wang Xiao-Gang Xiang Rui-Dong Mo Lan-Yi Lin Shi-San Bao Jie Lu Qing Xie |
| |
Affiliation: | 1. Department of Infectious Diseases, Ruijin Hospi-tal, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;2. Discipline of Pathology, School of Medical Sciences and Bosch Institute, University of Sydney, Australia |
| |
Abstract: | BACKGROUND: The IL-33/ST2 axis is involved in the patho-genesis of many diseases such as autoimmune diseases, cancer, and heart failure. However, studies of the IL-33/ST2 pathway in HBV-related acute-on-chronic liver failure (HBV-ACLF) are lacking. The present study aimed to determine the prognostic role of serum IL-33/soluble ST2 (sST2) in HBV-ACLF.METHODS: Serum levels of IL-33 and sST2 in healthy controls (HC, n=18), chronic hepatitis B (CHB, n=27) and HBV-ACLF (n=51) patients at the 1st and 4th week after enrollment were detected using ELISA, and clinical data were collected. The follow-up of HBV-ACLF patients lasted for 6 months at least.RESULTS: There was no significant difference of serum IL-33 level among HC, CHB and HBV-ACLF patients at week 1. However, serum sST2 level differed significantly among the three groups: highest in the HBV-ACLF group, moderate in the CHB group and lowest in the HC group. There was a re-verse correlation between serum sST2 level and the survival of HBV-ACLF patients. The level of serum sST2 in HBV-ACLF survivors was significantly declined from week 1 to week 4 following the treatment, whereas that in HBV-ACLF non-survivors remained at a high level during the same period. Fur-thermore, serum sST2 level was significantly correlated with laboratory parameters and the most updated prognostic scores (CLIF-C OF score, CLIF-C ACLF score and ACLF grades). The receiver operating characteristics curves demonstrated that serum sST2 level was a good diagnostic marker for predicting the 6-month mortality in HBV-ACLF patients, comparable to the most updated prognostic scores. Serum sST2 cut-off points for predicting prognosis in HBV-ACLF patients were 76 ng/mL at week 1 or 53 ng/mL at week 4, respectively. HBV-ACLF pa-tients with serum sST2 level above the cut-off point often had a worse prognosis than those below the cut-off point.CONCLUSION: Serum sST2 may act as a promising biomark-er to assess severity and predict prognosis of patients with HBV-ACLF and help for the early identification and optimal treatment of HBV-ACLF patients at high risk of mortality. |
| |
Keywords: | biomarker HBV-related acute-on-chronic liver failure interleukin-33 prognosis soluble ST2 |
本文献已被 CNKI 万方数据 ScienceDirect 等数据库收录! |
|